SCHEMBL8574441

SCHEMBL8574441

COC(=O)N[C@H](C(=O)N1CCC[C@H]1O)C(C)C

nearest known ligand 0.51

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
▸ CYP3A4 P08684 7/20 0.51
▸ CYP2C9 P11712 5/20 0.51
▸ NR1I2 O75469 2/20 0.51
▸ ABCB11 O95342 1/20 0.51
▸ OPRK1 P41145 1/20 0.51
▸ KCNH2 Q12809 1/20 0.51
▸ DPP4 P27487 3/20 0.50
▸ DPP8 Q6V1X1 1/20 0.50
▸ DPP9 Q86TI2 1/20 0.50
▸ CYP1A2 P05177 3/20 0.45
▸ CYP2D6 P10635 2/20 0.45
▸ PREP P48147 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12772923 0.85 CYP3A4 (0.51) CYP3A4CYP2C9NR1I2ABCB11OPRK1
SCHEMBL10140841 0.85 CYP3A4 (0.51) CYP3A4CYP2C9NR1I2ABCB11OPRK1
SCHEMBL19497190 0.85 CYP3A4 (0.51) CYP3A4CYP2C9NR1I2ABCB11OPRK1
SCHEMBL3269007 0.85 CYP3A4 (0.51) CYP3A4CYP2C9NR1I2ABCB11OPRK1
SCHEMBL2681581 0.85 CYP3A4 (0.51) CYP3A4CYP2C9NR1I2ABCB11OPRK1
SCHEMBL15765645 0.85 CYP3A4 (0.51) CYP3A4CYP2C9NR1I2ABCB11OPRK1
SCHEMBL17527163 0.85 DPP4 (0.52) CYP3A4CYP2C9NR1I2ABCB11OPRK1
SCHEMBL12558263 0.84 CYP3A4 (0.50) CYP3A4CYP2C9NR1I2ABCB11OPRK1
SCHEMBL12018398 0.84 CYP3A4 (0.50) CYP3A4CYP2C9NR1I2ABCB11OPRK1
SCHEMBL14758662 0.84 CYP3A4 (0.50) CYP3A4CYP2C9NR1I2ABCB11OPRK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2628481-B1 Trisubstituted heterocycles as replication inhibitors of hepatitis C virus HCV ABBVIE BAHAMAS LTD (BS) 2016-02-24 — — EP disclosed
EP-2455376-A1 Heterocyclic compounds as inhibitors of hepatitis C virus (HCV) Abbott Laboratories (US) 2012-05-23 — — EP disclosed
WO-2010144646-A2 ANTI-VIRAL COMPOUNDS ABBOTT LABORATORIES (US) 2010-12-16 — — WO disclosed
Send feedback